Increase of adhesion molecules, fibrinogen, type‐1 plasminogen activator inhibitor and orosomucoid in growth hormone (GH) deficient adults and their modulation by recombinant human GH replacement
- 19 May 2000
- journal article
- Published by Wiley in Clinical Endocrinology
- Vol. 52 (5) , 543-548
Abstract
OBJECTIVE GH deficiency (GHD) is usually associated with a higher incidence of cardiovascular disease (CVD). The aim of this study was to establish whether patients with GHD, like those with CVD, show an increase in fibrinogen (FBG), type‐1 plasminogen activator inhibitor (PAI‐1), acute phase response proteins (APR), and soluble adhesion molecules. The effect of recombinant human GH (rhGH) replacement, on these parameters was also investigated. PATIENTS AND DESIGN Concentrations of PAI‐1 antigen (Ag), adhesion molecules sE‐selectin, sP‐selectin, and intercellular adhesion molecule‐1 (sICAM‐1), FBG and levels of APR orosomucoid (ORM), and ‘negative APR’ transferrin (TRF) were established in 11 panhypopituitary (PHP) patients (eight men and three women, age median 39.0 years, body mass index (BMI) 27.49 ± 3.89 kg/m2) before and after 12‐month replacement with rhGH. Control values were obtained by examination of 33 healthy age and sex matched subjects (24 men and nine women with BMI 24.16 ± 1.99 kg/m2). RESULTS PHP patients had higher concentrations of ORM (0.80 ± 0.25, vs. 0.61 ± 0.20 g/l; P = 0.05), FBG (3.22 ± 0.48, vs. 2.57 ± 0.47 g/l; P = 0.001), PAI‐1 Ag (97.12 ± 33.23, vs. 44.11 ± 21.40 μg/l; P = 0.001), sE‐selectin (72.42 ± 28.35, vs. 42.80 ± 12.60 μg/l; P = 0.004), sP‐selectin (221.26 ± 75.12, vs. 104.79 ± 26.01 μg/l; P = 0.001) sICAM‐1 (409.75 ± 137.78, vs. 228.10 ± 37.54 μg/l; P = 0.001), and lower levels of TRF (2.14 ± 0.40, vs. 2.76 ± 0.39 g/l; P = 0.001) than controls. After 12‐month rhGH replacement the patients showed an increase of TRF (2.64 ± 0.84 g/l, P = 0.037) and decrease of soluble adhesion molecules (sE‐selectin 57.98 ± 27.04 μg/l, P = 0.01, sP‐selectin 121.74 ± 50.42 μg/l, P = 0.007; and sICAM‐1 279.95 ± 88.32 μg/l, P = 0.005), which then, similarly to the ORM (0.67 ± 0.12 g/l) and FBG level (2.82 ± 0.51 g/l), did not statistically differ from the values in the control group. CONCLUSION rhGH replacement led to modulation of the ‘inflammatory response’ in panhypopituitary patients. This modulation occurred locally at vascular endothelium level where after rhGH replacement, sE‐selectin, sP‐selectin and sICAM‐1 concentrations decreased, a similar effect as in the systemic inflammatory response, as was also apparent from the changes in acute phase response protein levels.Keywords
This publication has 40 references indexed in Scilit:
- Growth Hormone Therapy in Critically Ill PatientsNew England Journal of Medicine, 1999
- Increased Mortality Associated with Growth Hormone Treatment in Critically Ill AdultsNew England Journal of Medicine, 1999
- Defects of Insulin Action and Skeletal Muscle Glucose Metabolism in Growth Hormone-Deficient Adults Persist after 24 Months of Recombinant Human Growth Hormone TherapyThe Journal of Clinical Endocrinology & Metabolism, 1998
- Signal transduction through NF-κBImmunology Today, 1998
- Increased cerebrovascular mortality in patients with hypopituitarismClinical Endocrinology, 1997
- Low density lipoprotein particle size in hypopituitary adults receiving conventional hormone replacement therapyThe Journal of Clinical Endocrinology & Metabolism, 1996
- Insulin resistance in growth hormone-deficient adults: defects in glucose utilization and glycogen synthase activityThe Journal of Clinical Endocrinology & Metabolism, 1996
- The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A proteinImmunology Today, 1994
- The acute phase responseImmunology Today, 1994
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993